Skip to content

Study · Animal study (in vivo) · mouse · 2014

4 results

Biphasic effect of melanocortin agonists on metabolic rate and body temperature.

Lute B, Jou W, Lateef DM, Goldgof M, Xiao C, Piñol RA, Kravitz AV, Miller NR, Huang YG, Girardet C, Butler AA, Gavrilova O, Reitman ML

Cell metabolism26 Jun 2014Cited by 33 (Europe PMC)

PMID24981835 (opens in a new tab)PMCIDPMC4126889 (opens in a new tab)DOI10.1016/j.cmet.2014.05.021 (opens in a new tab)PepBankPUB-24981835
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal MTII caused an Mc4r-mediated rise in metabolic rate and body temperature (hypermetabolism and hyperthermia).

    In plain wordsIn mice, melanotan II injected into the belly raised metabolic rate and body temperature through the MC4 receptor.

    Peptide
    Melanotan II
    Outcome
    IncreaseMetabolic rate and body temperature after MTII
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal administration of the nonselective melanocortin agonist MTII causes a melanocortin-4 receptor (Mc4r)-mediated hypermetabolism/hyperthermia.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, a profound transient fall in metabolic rate and body temperature preceded the MTII-induced rise and persisted in mice lacking any one of Mc1r, Mc3r, Mc4r or Mc5r.

    In plain wordsIn mice, melanotan II first caused a short drop in metabolic rate and body temperature, even in mice lacking one melanocortin receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseTransient hypometabolism and hypothermia after MTII
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    This is preceded by a profound, transient hypometabolism/hypothermia that is preserved in mice lacking any one of Mc1r, Mc3r, Mc4r, or Mc5r.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, MTII selectively activated arcuate nucleus dopaminergic neurons.

    In plain wordsIn mice, melanotan II selectively switched on a group of dopamine-producing brain cells.

    Peptide
    Melanotan II
    Outcome
    IncreaseActivation of arcuate nucleus dopaminergic neurons by MTII
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MTII selectively activated arcuate nucleus dopaminergic neurons

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 04AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome

    In mice, dopamine antagonists prevented the hypometabolism and hypothermia that follow MTII.

    In plain wordsIn mice, dopamine-blocking drugs prevented the drop in metabolism and temperature caused by melanotan II.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII-induced hypometabolism and hypothermia with dopamine antagonists
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight

    Source sentences

    Summary
    The hypometabolism/hypothermia was prevented by dopamine antagonists

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.